翻訳と辞書 |
Catridecacog : ウィキペディア英語版 | Catridecacog
Catridecacog (brand name Tretten in the US and NovoThirteen in Europe〔NHS (New Drugs Online Report for catridecacog ) Page accessed July 2, 2015〕) is a class of recombinant factor XIII A-subunit based biopharmaceutical medicine, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency, which is a kind of Factor XIII deficiency. The medication prevents bleeding in patients with this condition, and has been approved by the U.S. Food and Drug Administration (FDA) for this use in the US in 2014.〔 (Catridecacog: First drug to treat rare genetic blood clotting disorder ). ''The Pharmacist'' February 01, 2014 〕 It was brought to market by Novo Nordisk.〔 ==References==
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Catridecacog」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|